๐ BIOGENYSIS ๐
It's official! The website is now up and running! Great work Enzolytics team, this is an incredible upgrade. ๐พ๐ฅ
LINK ๐ https://t.co/ngYjg1D865
Winning 2023 ๐
$ENZC $SAGA #ENZC#SAGA
@TheMattOMalley More information will be available on our website being launched this month: https://t.co/6lz7neYkQu. The following infographic explains this. Our press releases and filings have disclosed this as well. #ENZC
Today holds great significance as we take a moment to acknowledge and bring attention to #WorldAlzheimersDay. This day provides a valuable opportunity to educate ourselves about this illness, dispel negative stereotypes, and increase awareness. Alzheimer's disease can exacerbate the feeling of isolation that many individuals already experience in our increasingly disconnected society. It's important to note that the brain changes associated with Alzheimer's can occur up to 20 years before any symptoms manifest. We remain steadfast in our commitment to identifying early biomarkers and developing innovative treatments for this deadly disease. #Chandradrishti #AI @ZainKhalpey RiinEhin
$ENZC $SAGA The company has "near-term objectives of collaborating with pharmaceutical companies." I think part of the reason why the transaction was valued at $450MM was because the route to these partnerships was taken into consideration, along with the #billions of dollars in potential #licensing deals. That's what's on the table.
I honestly think many will be overwhelmed when big pharma names start dropping. Everything is already set in motion. It's time to buckle up emotionally, this $450MM deal to go to #NASDAQ is just an hors d'oeuvre๐
Congrats, @drgauravchandra. You're a winner ๐
We have a well-defined strategy and the necessary technology in place for producing numerous therapeutics for successfully treating numerous viruses. Completing the business combination with Sagaliam comes at a critical time. https://t.co/jhMoRxaH3f
We have a well-defined strategy and the necessary technology in place for producing numerous therapeutics for successfully treating numerous viruses. Completing the business combination with Sagaliam comes at a critical time. https://t.co/jhMoRxaH3f
#BGEN continues to make a significant impact in drug discovery and development by utilizing advanced AI technology. Our focus is on safeguarding our assets while expanding our IP portfolio to include #AI -driven monoclonal antibodies. With these antibodies, we aim to revolutionize the fight against #HIV , #COVID19 mutations, and other viruses. Collaborating with pharmaceutical companies, our focus is to cover all viruses in our repository, providing patients with necessary diagnostics and therapies. Our "AI Platform is constantly evolving with disruptive innovations" in healthcare. We are proud to be at the forefront of this crucial work and look forward to continuing to positively impact the world. #ENZC #NASDAQ https://t.co/Z2StDmMw5J
$ENZC ๐ฅPRESS RELEASE๐ฅ
๐๐ฃ๐ฏ๐ค๐ก๐ฎ๐ฉ๐๐๐จ ๐ผ๐ฃ๐ฃ๐ค๐ช๐ฃ๐๐๐จ ๐ฉ๐๐ ๐๐๐๐ฃ๐๐ฃ๐ ๐ค๐ ๐ฉ๐๐ ๐ฝ๐ช๐จ๐๐ฃ๐๐จ๐จ ๐พ๐ค๐ข๐๐๐ฃ๐๐ฉ๐๐ค๐ฃ ๐ผ๐๐ง๐๐๐ข๐๐ฃ๐ฉ ๐ฌ๐๐ฉ๐ ๐๐๐๐๐ก๐๐๐ข ๐ผ๐๐ฆ๐ช๐๐จ๐๐ฉ๐๐ค๐ฃ ๐พ๐ค๐ง๐ฅ (๐๐ผ๐๐ผ)
Enzolytics, Inc. announces today that it has executed the binding business combination agreement for the sale of Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO"), the operating subsidiaries of Enzolytics Inc., to Sagaliam Acquisition Corp (NASDAQ: SAGA) in a transaction valued at $450,000,000. The combined company is expected to trade on NASDAQ. The entities have begun the de-SPAC process and are moving on with the closing of this project.
$SAGA #BGEN
Monumental Transformation ๐พ๐พ
We express our gratitude for our valued shareholders' continued and unwavering backing, especially amidst trying circumstances. Our commitment to pressing ahead with our plans and vision perseveres unwaveringly. With resolute determination, we forge ahead towards greater heights!โIf you want to go fast, go alone; if you want to go far, go together and take the giant leap.The #SAGA #BGENs
https://t.co/ADUjsBoeR0
The Company has executed a binding business combination agreement for the purchase of #BGEN & VIRO, operating subsidiaries of Enzolytics Inc. #ENZC The combined company is expected to trade on NASDAQ. https://t.co/8Xbj9TKpti
$ENZC ๐DEAL COMPLETE ๐
๐๐ผ๐๐ผ๐๐๐ผ๐ ๐ผ๐พ๐๐๐๐๐๐๐๐๐ ๐พ๐๐๐. ๐ผ๐๐๐๐๐๐พ๐๐ ๐๐๐๐พ๐๐๐๐๐ ๐๐ ๐ฟ๐๐๐๐๐๐๐๐๐ ๐ฝ๐๐๐๐๐๐๐ ๐พ๐๐๐ฝ๐๐๐ผ๐๐๐๐ ๐ผ๐๐๐๐๐๐๐๐๐ฅ๐ฅ๐ฅ
The Company has executed a binding business combination agreement for the purchase of Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO"), operating subsidiaries of Enzolytics Inc. (OTC PK: ENZC). The combined company is expected to trade on NASDAQ.
Congrats everyone!
Major milestones just achieved. ๐
$SAGA Executive Team, @enzolytics Team, @drgauravchandra, and all patient shareholder! ๐ฅ๐ฅ๐ฅ๐ฅ
Winning! ๐
https://t.co/3q01PCFO6x